Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06244277
Other study ID # 2023-SR-850
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 22, 2023
Est. completion date December 31, 2025

Study information

Verified date January 2024
Source The First Affiliated Hospital with Nanjing Medical University
Contact Xiuqin Wang, doctor
Phone +86-25-68306156
Email xiuqinw@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of traditional Chinese medicine in the treatment of adolescent sleep disorders and the effect of sleeping pills withdrawal.


Description:

All subjects giving written informed consent. In this multicenter,controlled, prospective cohort study, the outpatient and inpatient adolescent sleep disorder patients' baseline demographic data were collected, including age, gender, education background, and medication history. Venous blood samples were collected and sent to laboratory test for blood routine, and blood biochemistry at Baseline and Week 4. The Pittsburgh sleep quality index (PSQI) was used to assess the patients' sleep quality at baseline, month 1, month 3 and month 6. Objective sleep quality data is assessed by wearing a Sleep wearable devices. The classic Morningness-Eveningness Questionnaire and wearable devices was used to assess the patients' chronotype at baseline and week 4.Subjects who visit the TCM clinic of this project received Suanzaoren Decoction and Huanglian Wendan Decoction and other decoctions orally twice daily for 4 weeks. Add or subtract Chinese herbal medicine according to the different clinical manifestations of each patient. Subjects from TCM clinic who had previously taken Western medicine hypnotics continued taking them, and for those who had not taken before, Western medicine hypnotics shall not be given/prescribed. Subjects who visit the Western medicine clinic of this project received cognitive behavioral therapy, if for various reasons can not accept cognitive behavioral therapy, or have received cognitive behavioral therapy is not effective, according to the doctor to consider drug treatment, taking Zolpidem Tartrate Tablets 0.25mg/kg, the maximum dose was 10mg / day ; according to the doctor 's clinical consideration, anxiety and depression drugs can be added. For patients under 18 years of age, under the careful consideration of the doctor for drug treatment, taking oxazepam tablets, 3.75-15mg / day, if necessary, signed informed consent of clinical medication. Adverse reactions were closely monitored during medication.The participants will have a follow-up visit every two weeks, and the prescription would be adjusted according to the condition of illness.Cessation rate of Western medicine hypnotics was assessed at Month 6.


Recruitment information / eligibility

Status Recruiting
Enrollment 106
Est. completion date December 31, 2025
Est. primary completion date December 31, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 13 Years to 25 Years
Eligibility Inclusion Criteria: - Outpatients or inpatients. - It meet the diagnostic criteria of ' International Classification of Sleep Disorders, Third Edition ' ( ICSD-3 ).. - Informed consent, voluntary participation in the study. Exclusion Criteria: - Sleep disorders are caused by systemic diseases such as body pain, fever, cough, surgery and external environmental interference.Sleep apnea syndrome leads to insomnia. - Severe depression, suicidal tendency or having committed suicide. - Pregnant and lactating women. - It has serious primary heart, liver, lung, kidney, blood or serious diseases affecting its survival, such as: tumor or AIDS, SCR > 1.5n (n is the upper limit of normal value), ALT > 2n (n is the upper limit of normal value), WBC < 3.0 × 109 / L; - Those who cannot give full informed consent due to mental disorders. - According to the researcher's judgment, other situations that are not suitable for the group, such as the change of working environment. - Subjects who are participating in other clinical studies.

Study Design


Intervention

Drug:
Suanzaoren Decoction and Huanglian Wendan Decoction
Twice daily. Chinese herbal medicine includes: includes: 25 grams of Suanzaoren, 10 grams of chuanxiong, 30 grams of fushen, 10 grams of Polygala tenuifolia, 10 grams of Pinellia ternata, 12 grams of tangerine peel, 15 grams of Zhuru, 30 grams of forged keel, 30 grams of forged oyster,10 grams of aurantii fructus, 6 grams of coptis chinensis, 30 grams of Albizzia bark.Add or subtract Chinese herbal medicine according to the different clinical manifestations of each patient.
Zolpidem
Zolpidem 10Mg Tab 10mg tablet once daily

Locations

Country Name City State
China The First Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
The First Affiliated Hospital with Nanjing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline in the total score of the Pittsburgh sleep quality index (PSQI) at Month 1 The Pittsburgh sleep quality index (PSQI) is a validated,self-reported instrument assessing the sleep quality over the past 4 week period. Possible scores range from 0(the best sleep quality) to 21(the worst possible sleep) quality).The higher the score of PSQI, the worse the sleep quality. Change=(Month 1 Score-Baseline Score) Baseline and Month 1
Primary Insomnia severity index ( ISI ) score reduction rate at Month 1 Insomnia severity index ( ISI ) is to assess the nature and symptoms of sleep disorders in subjects. Score reduction rate of Insomnia severity index ( ISI )=(Baseline number-Month 1number)/Baseline number of participants Month 1
Secondary Cessation rate of Western medicine hypnotics at Month 6 Cessation is defined as an absence of any Western medicine hypnotics that was sustained for 3 consecutive months or more. Cessation rate of Western medicine hypnotics=(Month 6 number-Baseline number)/Baseline number of Participants use Western medicine hypnotics. Month 6
Secondary Athens Insomnia Scale ( AIS ) score at Month 1 Athens Insomnia Scale ( AIS ) is to assess subjective feelings about sleep.Using 0(no sleep disorders)-3(insomnia) rating form. Baseline and Month 1
Secondary Change from Baseline of the ALT at 4 weeks Alanine aminotransferase, ALT in U/L Baseline and Week 4
Secondary Change from Baseline of the AST at 4 weeks Aspartate aminotransferase, AST in U/L Baseline and Week 4
Secondary Change from Baseline of the BUN at 4 weeks Blood urea nitrogen, BUN in mmol/L Baseline and Week 4
Secondary Change from Baseline of the Scr at 4 weeks Serum creatinine, Scr in µmol/L Baseline and Week 4
Secondary Genome-wide association study Illumina HumanHap550-Duo BeadChips was used to perform the whole genome genotyping in deCODE genetics(Reykjavi'k, Iceland) Month 6
Secondary Item Patient Health Questionnaire ( PHQ-9 ) The PHQ-9 is a validated, self-reported questionaire aidding Auxiliary depression diagnosis and symptom severity assessment. Possible scores range from 0 (no depressive symptoms) to 27(major depression). Baseline and Week 4
Secondary Change from Baseline in the score of Morningness-Eveningness Questionaire (MEQ) The MEQ is a validated, self-reported questionaire assessing personal chronotype in the recent period. Possible scores range from 16 (extreme eveningness) to 86 (extreme morningness). Change = (Week 4 Score - Baseline Score). Positive score change indicates a shift from eveningness to morningness. Baseline and Week 4
See also
  Status Clinical Trial Phase
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Recruiting NCT04786314 - The Effect of Hot and Cold Water Application on Pregnant Women With Restless Leg Syndrome N/A
Recruiting NCT05775731 - Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
Recruiting NCT03326765 - Characterizing Sleep Disorders in Children and Adults With Tuberous Sclerosis Complex (TSC) N/A
Completed NCT03673397 - The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression N/A
Completed NCT03903263 - Sleep Disturbances in Dermatology Patients
Not yet recruiting NCT06012513 - Sleep Disorders and Quality of Life in Patients With Multiple Sclerosis
Not yet recruiting NCT05950932 - Effects of Melissa Extract on Sleep Characteristics Phase 4
Completed NCT01463839 - Sleep Disorder and Oral Habits in Children N/A
Completed NCT00940589 - Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor Phase 2
Recruiting NCT06093633 - A Prospective Study to Evaluate the WP in Comparison to PSG in Patients Suspected of Sleep Disorders
Completed NCT06108115 - Smartphone-Based Intervention for Sleep Disturbance in Individuals Recovering From Alcohol Use Disorder N/A
Completed NCT05511818 - Radicle Rest: A Study of Cannabinoids on Sleep and Health Outcomes N/A
Active, not recruiting NCT04291014 - Light Therapy for PD - Dose Selection N/A
Completed NCT04560595 - Remote Guided Caffeine Reduction N/A
Completed NCT06008470 - Investigation of Respiratory Muscle Strength, Exercise Capacity, Physical Activity and Sleep Quality Level in Individuals With Covid-19 Infection
Recruiting NCT06129942 - Light Therapy in Parkinson's Disease N/A
Recruiting NCT04318067 - Melatonin in ADHD and Sleep Problems Phase 4
Completed NCT03857802 - Efficiency of a Nursing Intervention in Sleep Hygiene N/A
Completed NCT03532269 - Validation of the Sleep Assessment Algorithm in the Medical Application Nightly N/A